2021
Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness
Luykx J, Loef D, Lin B, van Diermen L, Nuninga J, van Exel E, Oudega M, Rhebergen D, Schouws S, van Eijndhoven P, Verwijk E, Schrijvers D, Birkenhager T, Ryan K, Arts B, van Bronswijk S, Kenis G, Schurgers G, Baune B, Arns M, van Dellen E, Somers M, Sommer I, Boks M, Gülöksüz S, McLoughlin D, Dols A, Rutten B. Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness. Biological Psychiatry 2021, 91: 531-539. PMID: 34955169, DOI: 10.1016/j.biopsych.2021.10.013.Peer-Reviewed Original ResearchConceptsMajor depressive episodeHamilton Depression Rating Scale scoresDepression Rating Scale scoresRating Scale scoresPolygenic risk scoresPRS-SCZECT outcomeElectroconvulsive therapyScale scoreSevere major depressive episodeUnipolar major depressive episodeMajor depressive disorderSecondary outcomesAntidepressant responseECT treatmentDepressive episodeSubgroup analysisECT effectivenessPsychotic featuresDepressive disorderTreatment responseMAIN OUTCOMEEffective treatmentRisk scoreTherapy effectiveness
2020
Phenome-wide and genome-wide analyses of quality of life in schizophrenia
Pazoki R, Lin B, van Eijk K, Schijven D, de Zwarte S, Alizadeh B, van Amelsvoort T, Bartels-Velthuis A, van Beveren N, Bruggeman R, Cahn W, de Haan L, Delespaul P, Luykx J, Myin-Germeys I, Kahn R, Schirmbeck F, Simons C, van Os J, van Winkel R, Guloksuz S, Luykx J. Phenome-wide and genome-wide analyses of quality of life in schizophrenia. BJPsych Open 2020, 7: e13. PMID: 33295273, PMCID: PMC7791571, DOI: 10.1192/bjo.2020.140.Peer-Reviewed Original ResearchPolygenic risk scoresRisk scoreClinical phenotypeNon-genetic contributing factorsMajor depressive disorderQuality of lifeDepressive disorderHealthy controlsVulnerable patientsStudy populationHypothesis-generating approachPatientsPsychotic disordersQoLSmall studyClinical interventionsSchizophreniaGenotypic determinantsScoresContributing factorDisordersPhenotypeAssociationThiol/Disulfide Homeostasis in Bipolar and Unipolar Depression
Erzin G, Özkaya G, Topçuoğlu C, Yüksel R, Erel Ö, Yurt E, Göka E, Gülöksüz S. Thiol/Disulfide Homeostasis in Bipolar and Unipolar Depression. Clinical Psychopharmacology And Neuroscience 2020, 18: 395-401. PMID: 32702218, PMCID: PMC7383011, DOI: 10.9758/cpn.2020.18.3.395.Peer-Reviewed Original ResearchDisulfide/total thiol ratiosTotal thiol ratiosThiol-disulfide homeostasisBipolar depressionHealthy controlsUnipolar depressionNative thiol ratioBipolar disorderDisulfide levelsThiol ratioDepressive disorderNative thiolAnkara Numune TrainingThiol/disulfide homeostasisDisulfide/native thiol ratioOxidative stress markersUnipolar depressive disorderDSM-5 criteriaLevels of disulfideUD groupOutpatient clinicClinical entityDepressive episodeResearch HospitalTherapeutic differences
2013
Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability
Guloksuz S, Wichers M, Kenis G, Russel M, Wauters A, Verkerk R, Arts B, van Os J. Depressive Symptoms in Crohn's Disease: Relationship with Immune Activation and Tryptophan Availability. PLOS ONE 2013, 8: e60435. PMID: 23544139, PMCID: PMC3609785, DOI: 10.1371/journal.pone.0060435.Peer-Reviewed Original ResearchConceptsCrohn's diseaseDisease activityImmune activationDepressive symptomsDepression scoresTrp availabilityΑ treatmentTryptophan availabilityNegative APPsAnti-tumor necrosis factorPast depressive disorderTNF-α treatmentSymptoms of depressionQuality of lifeCD patientsIBDQ scoreImmune markersComorbid depressionDepressive disorderNecrosis factorInflammatory reactionPatientsSymptomsDiseaseTreatment